0001628280-24-000950.txt : 20240109
0001628280-24-000950.hdr.sgml : 20240109
20240109161103
ACCESSION NUMBER: 0001628280-24-000950
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231228
FILED AS OF DATE: 20240109
DATE AS OF CHANGE: 20240109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fox-Collis Aaron
CENTRAL INDEX KEY: 0001963698
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21088
FILM NUMBER: 24523381
MAIL ADDRESS:
STREET 1: 2000 CENTRAL AVE
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
FORMER NAME:
FORMER CONFORMED NAME: Fox-Colis Aaron
DATE OF NAME CHANGE: 20230126
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fresh Tracks Therapeutics, Inc.
CENTRAL INDEX KEY: 0000819050
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 930948554
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5777 CENTRAL AVENUE
STREET 2: SUITE 102
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (720) 505-4755
MAIL ADDRESS:
STREET 1: 5777 CENTRAL AVENUE
STREET 2: SUITE 102
CITY: BOULDER
STATE: CO
ZIP: 80301
FORMER COMPANY:
FORMER CONFORMED NAME: Brickell Biotech, Inc.
DATE OF NAME CHANGE: 20190830
FORMER COMPANY:
FORMER CONFORMED NAME: VICAL INC
DATE OF NAME CHANGE: 19940211
4
1
wk-form4_1704834651.xml
FORM 4
X0508
4
2023-12-28
0
0000819050
Fresh Tracks Therapeutics, Inc.
FRTX
0001963698
Fox-Collis Aaron
2000 CENTRAL AVENUE, SUITE 100
BOULDER
CO
80301
0
1
0
0
VP of Finance & CAO
0
Restricted Stock Units
2023-12-28
4
D
0
8000
0.91
D
Common Stock
8000
0
D
Prior to December 28, 2023, each restricted stock unit ("RSU") represented a contingent right to receive one share of issuer common stock upon settlement. Effective on December 28, 2023, the issuer's board of directors terminated the Fresh Tracks Therapeutics, Inc. (the "Company") 2020 Omnibus Long-Term Incentive Plan (the "Plan") and all unvested RSUs granted under the Plan. The value of the terminated RSUs was replaced with a right to a cash payment valued by multiplying the number of RSUs by the closing price of the Company's common stock on such date (the "Cash Payment").
The Cash Payment will vest in full on the first anniversary of the grant date of the RSUs.
/s/ Griffin D. Foster, Attorney-in-Fact for Aaron Fox-Collis (power of attorney previously filed)
2024-01-09